About MetaVia (NASDAQ: MTVA)
MetaVia is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cardiometabolic and metabolic-related diseases with significant unmet medical need. The company leverages validated biological pathways and clinically tested compounds to pursue more efficient development timelines, differentiated safety profiles, and meaningful patient outcomes.
MetaVia’s strategy centers on advancing therapies that sit at the intersection of metabolism, cardiovascular health, and chronic disease, areas that continue to grow in prevalence and economic burden worldwide.
Focused Development in Large Metabolic Disease Markets
MetaVia is advancing a clinical-stage pipeline focused on metabolic and cardiometabolic diseases, including conditions associated with metabolic dysfunction and obesity. These disease areas represent significant global health challenges and continue to place increasing strain on healthcare systems worldwide, driving sustained demand for new therapeutic approaches.
The company’s investigational programs target metabolic pathways that have been extensively studied in humans, including hormonal and receptor-based mechanisms involved in appetite regulation, glucose control, and broader metabolic function. By focusing on pathways with established relevance to human biology, MetaVia aims to evaluate its candidates across clearly defined and measurable clinical endpoints.
MetaVia maintains a focused development strategy centered on a limited number of active clinical programs rather than a broad, multi-asset platform. This approach allows the company to concentrate resources on advancing select candidates through clinical development, with an emphasis on generating interpretable clinical data and well-defined development milestones.
As scientific understanding of metabolic disease continues to evolve, MetaVia is advancing its programs within therapeutic areas that remain a central focus of innovation across the pharmaceutical industry. Through continued clinical evaluation and disciplined development execution, the company seeks to address unmet needs across metabolic and cardiometabolic disease while progressing toward meaningful clinical outcomes.
Building a Focused Metabolic Disease Pipeline
MetaVia’s clinical pipeline centers on two investigational therapies that act on well-defined metabolic and hormonal pathways implicated in obesity and metabolic dysfunction-associated liver disease. Both programs are derived from mechanisms shown to influence glucose control, appetite regulation, liver health, and metabolic biomarkers.
DA-1726 – Dual GLP-1R / GCGR Agonist for Obesity:
- DA-1726 is a novel oxyntomodulin (OXM) analogue designed to engage both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This dual action is intended to reduce appetite through incretin signaling while increasing energy expenditure, embedding two complementary metabolic effects within a once-weekly injectable therapy. In Phase 1 multiple ascending dose (MAD) studies, MetaVia has reported statistically significant results showing meaningful weight loss, improvements in glucose control, and reductions in waist circumference — data the company has highlighted as supportive of DA-1726’s potential clinical impact in obesity.
Vanoglipel (DA-1241) – Oral GPR119 Agonist for MASH:
- Vanoglipel (referred to on the site and in disclosures as DA-1241) is an orally administered agonist of the G-Protein-Coupled Receptor 119 (GPR119). Activation of GPR119 promotes increased secretion of key gut hormones — including GLP-1, GIP, and PYY — which have roles in glucose homeostasis, lipid metabolism, and satiety. MetaVia has reported that in Phase 2a clinical studies in patients with presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH), vanoglipel demonstrated direct hepatic effects along with beneficial changes in glucose metabolism and liver health markers.
Together, these two candidates represent MetaVia’s current clinical focus on addressing obesity and metabolic liver disease through differentiated mechanisms that modulate gut-liver-metabolic pathways. While both are investigational and subject to the outcome of ongoing and future clinical studies, they embody the company’s targeted approach to advancing therapies for cardiometabolic ailments.
See more on what they have in their legacy assets
Management Team Guiding MetaVia (NASDAQ: MTVA)
Hyung Heon Kim
Chief Executive Officer and President
Prior to his appointment as Chief Executive Officer and President of the Company, Mr. Kim was the General Counsel and a Senior Vice President of Dong-A ST and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production and sale of pharmaceuticals, medical devices and APIs. Mr. Kim has been serving as a member of the Company’s Board since July 2021. Mr. Kim previously served as Executive Director of Dong-A ST from 2018 through 2020 and as Head of International Legal Affairs for Dong-A Socio Holdings Co., Ltd., a Korean-based holdings company for the Dong-A Socio group of companies from 2012 to 2018. During his time at Dong-A ST and Dong-A Socio Holdings, he negotiated many significant transactions, including licensing and investment transactions.
Since April 2021, Mr. Kim has served as a director of AnaPath Services GmbH, a private, Swiss-based provider of scientific research and development services. Mr. Kim previously served as legal counsel to SK Energy Co., Ltd. and SK Innovation Co., Ltd. He received his Bachelor of Law degree from Soongshil University in Korea, and obtained his Juris Doctor from Washington University School of Law.
Mi-Kyung Kim
Chief Scientific Officer
Dr. Mi-Kyung Kim has served as a Vice President, leading the overall new drug discovery research for metabolic and immune-mediated diseases at Dong-A ST. She has more than 25 years of experience in the pharmaceutical industry. She has a high level of understanding of new drug development, experiencing both domestic and global clinical development, as well as overall new drug development from initial drug discovery to new drug approval while leading the project. She has specialized research experience focusing on chronic endocrine/cardiometabolic disease era such as diabetes, obesity, NASH, chronic kidney disease and osteoporosis.
During her career at Dong-A, she has led numerous projects, including a novel dipeptidyl peptidase inhibitor (evogliptin, Suganon®), which became the world ninth approved product for the treatment of type 2 diabetes. DA-1241 and DA-1726 are new drug candidates for metabolic diseases, and she has been establishing drug evaluation and development strategies while establishing the concept of drugs from the initial target selection stage of these two projects to the present. Academically, after she graduated from the College of Pharmacy at Ewha Womans University in Korea, she studied cancer metastasis and beta cell biology/proteomics in the same graduate school.
Marshall H. Woodworth
Chief Financial Officer
Marshall has more than 35 years of experience in financial roles of increasing responsibility including over 20 years of experience in life sciences and related sectors. Prior to joining MetaVia, Marshall held CFO roles with Nevakar Inc., Braeburn Pharmaceuticals Inc., Aerocrine AB and Furiex Pharmaceuticals Inc. During his career, Marshall has worked for a number of companies including: Eli Lilly, Dow Chemical, Monsanto, Milliken and others. Marshall brings a wealth of experience in private and public company management and stewardship and has extensive experience working with investors and analysts in the life science sector.
Throughout his career, Marshall has contributed to the success of companies by acting as a key resource and advisor to management, working closely with R&D and operations, and ensuring that finance functions are informed by a deep understanding of programmatic operations.
Marshall holds a Bachelor of Science degree from the University of Maryland College Park and an MBA from Indiana University in Bloomington.
Chris Fang, MD
Advisor/Consulting Chief Medical Officer
Dr. Chris Fang is a physician-scientist with over 20 years of experience in clinical development, R&D, and medical affairs. Before joining MetaVia, he served as Chief Medical Officer and President of R&D at Sidekick Health, collaborating with partners such as Eli Lilly, AstraZeneca, and Pfizer. Previously, he was Vice President of Global Medical Affairs at Eli Lilly, where he established an integrated clinical evidence strategy for key products in the cardiometabolic space. Before that, Dr. Fang was the Global Head of R&D Solutions at IQVIA and the Chief Executive Officer and co-founder of Acer Health. Earlier in his career, he served as Worldwide Vice President of Strategic Medical Sciences at Johnson & Johnson, and also held various clinical development positions at Medtronic, Mitsubishi Pharma, and Idenix Pharmaceuticals.
Dr. Fang earned a Bachelor of Arts from the University of California, Los Angeles, a Master of Health Science from Johns Hopkins School of Public Health, an MD from Weill Cornell Medical College, and an MBA from the Wharton School at the University of Pennsylvania.
Sources
- https://finance.yahoo.com/quote/MTVA/
- https://metaviatx.com/
- https://finance.yahoo.com/news/mtva-positive-results-48-mg-113000822.html
- https://metaviatx.com/clinical-pipeline/legacy-assets/
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Compensation: Pursuant to agreement between JRZ Capital and Virtus Media Group LLC, Virtus media Group has been hired to publicly disseminate information about MetaVia, Inc. (NASDAQ: MTVA) via digital communications starting 2026-2-2 ending 2026-2-4. Virtus Media Group has been paid $30,000 USD.
